Decoy Therapeutics INC. (DCOY) — 8-K Filings

All 8-K filings from Decoy Therapeutics INC.. Browse 40 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (40)

8-K Filing — Apr 2, 2026
Salarius Pharmaceuticals Files 8-K — Dec 19, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on December 19, 2025, reporting on the submission of matters to a vote of security holders, Regulation FD disclosure
Salarius Pharmaceuticals Announces Board and Executive Changes — Nov 19, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. announced on November 18, 2025, changes in its board of directors and executive compensation arrangements. The filing details the
8-K Filing — Nov 17, 2025
Salarius Pharmaceuticals Reports Multiple Material Events — Nov 13, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on November 13, 2025, reporting several material events as of November 11, 2025. These include entering into a mater
Salarius Pharmaceuticals Reports Director Changes and Compensation Updates — Oct 21, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on October 21, 2025, reporting changes in its board of directors and executive compensation arrangements. The filing
Salarius Pharmaceuticals Files 8-K — Oct 14, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on October 14, 2025, reporting other events and financial statements as of October 10, 2025. The company, formerly k
Salarius Pharmaceuticals Files 8-K — Oct 6, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on October 6, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
Salarius Pharmaceuticals Files 8-K — Sep 18, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on September 17, 2025, reporting on a material definitive agreement, modifications to security holder rights, and fi
Salarius Pharmaceuticals Changes Office Address — Sep 9, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on September 9, 2025, reporting an event on September 4, 2025. The filing indicates a change in the company's princi
Salarius Pharmaceuticals Files 8-K: "Other Events" — Aug 27, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on August 27, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these
Salarius Pharmaceuticals Files 8-K — Aug 22, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on August 22, 2025, to report other events and financial statements. The company, formerly known as Flex Pharma, Inc
Salarius Pharmaceuticals Board Shake-up — Aug 18, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. announced on August 17, 2025, a change in its board of directors. Specifically, Dr. Jeffrey T. Vaught has resigned from his posit
Salarius Pharmaceuticals Files 8-K with Key Corporate Updates — Aug 15, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on August 15, 2025, reporting material modifications to security holder rights and other events. The filing also inc
Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales — Jul 31, 2025 Risk: medium
On July 31, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition, as well as unregistered sales of e
Salarius Pharmaceuticals Files 8-K — Jul 29, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on July 29, 2025, reporting on material definitive agreements and modifications to security holder rights. The filin
Salarius Pharmaceuticals Relocates Offices — Jul 28, 2025 Risk: low
On July 28, 2025, Salarius Pharmaceuticals, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2450 Holcomb
Salarius Pharmaceuticals Files 8-K: Material Agreement & Security Holder Changes — Jul 21, 2025 Risk: medium
On July 18, 2025, Salarius Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The filing also indicates modifications to the rights of security
Salarius Pharmaceuticals Files 8-K — Jul 14, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on July 14, 2025, reporting other events and financial statements as of July 10, 2025. The company, formerly known a
Salarius Pharmaceuticals Reports Shareholder Vote Matters — Jul 8, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's
Salarius Pharmaceuticals Files 8-K — Jun 16, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on June 16, 2025, reporting an event on June 11, 2025. The filing is categorized under 'Other Events' and does not p
Salarius Pharmaceuticals Files 8-K — Jun 11, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on June 11, 2025, reporting a material definitive agreement and financial statements. The filing indicates a change
Salarius Pharmaceuticals Faces Delisting Notice — Apr 25, 2025 Risk: high
Salarius Pharmaceuticals, Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company, form
Salarius Pharmaceuticals Faces Delisting Concerns — Mar 28, 2025 Risk: high
Salarius Pharmaceuticals, Inc. filed an 8-K on March 28, 2025, reporting a material definitive agreement and a notice of delisting or failure to meet continued
Salarius Pharmaceuticals Files 8-K — Mar 11, 2025 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on March 11, 2025, reporting on events that occurred on March 10, 2025. The filing includes financial statements and
Salarius Pharmaceuticals Files 8-K on Operations and Equity Sales — Jan 17, 2025 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on January 17, 2025, reporting on its results of operations and financial condition, as well as unregistered sales o
8-K Filing — Jan 13, 2025
Salarius Pharmaceuticals Files 8-K on Shareholder Vote Matters — Dec 23, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on December 23, 2024, reporting on matters submitted to a vote of security holders as of December 20, 2024. The fili
Salarius Pharmaceuticals Files 8-K with Material Agreement — Dec 13, 2024 Risk: medium
On December 12, 2024, Salarius Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing.
Salarius Pharmaceuticals Files 8-K on Shareholder Nominations — Sep 27, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on September 27, 2024, to report on shareholder nominations pursuant to Exchange Act Rule 14a-11 and other events. T
Salarius Pharmaceuticals Raises $1M in Direct Offering — Aug 15, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. announced on August 13, 2024, that it entered into a securities purchase agreement with an institutional investor for a registere
Salarius Pharmaceuticals to be Acquired by Evren Technologies — Aug 14, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. announced on August 13, 2024, that it has entered into a definitive agreement to be acquired by Evren Technologies, Inc. The tran
Salarius Pharmaceuticals Files 8-K — Jul 25, 2024 Risk: low
Salarius Pharmaceuticals, Inc. filed an 8-K on July 25, 2024, reporting other events and financial statements. The company, formerly known as Flex Pharma, Inc.,
Salarius Pharmaceuticals to be Acquired by Big Rock Partners — Jul 23, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. announced on July 22, 2024, that it has entered into a definitive agreement to be acquired by Big Rock Partners, LLC. The transac
Salarius Pharmaceuticals to be Acquired by Evrensel Group — Jul 19, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by Evrensel Group, Inc. The transactio
Salarius Pharmaceuticals to be Acquired by Evren Technologies — Jul 11, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. announced on July 9, 2024, that it has entered into a definitive agreement to be acquired by Evren Technologies, Inc. The transac
Salarius Pharmaceuticals Files 8-K — Jun 17, 2024 Risk: low
On June 17, 2024, Salarius Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No s
Salarius Pharmaceuticals Files 8-K Report — Jun 14, 2024 Risk: medium
On June 14, 2024, Salarius Pharmaceuticals, Inc. filed an 8-K report detailing material modifications to security holder rights and other events. The company, f
Salarius Pharmaceuticals Faces Delisting Notice — Mar 6, 2024 Risk: high
Salarius Pharmaceuticals, Inc. filed an 8-K on March 6, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company, previ
Salarius Pharmaceuticals Files 8-K on Officer Changes and Other Events — Feb 23, 2024 Risk: medium
Salarius Pharmaceuticals, Inc. filed an 8-K on February 23, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, "Depa

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX